Oral Abstracts
2021
Journal of Diabetes Investigation
OBJECTIVE: Sodium glucose cotransporter 2 (SGLT2) inhibitor is on the rise as a representative oral antidiabetic agent (OAD) exhibiting beneficial effects on glycemic control and cardiometabolic protective effects in recent few years. This study aimed to evaluate the efficacy and safety of 3-year follow-up of empagliflozin and dapagliflozin as add-on in patients with type 2 diabetes (T2D) inadequately controlled despite triple OADs. METHODS: Eligible patients for this 3-year, open-label,
more »
... tive observational study were adult T2D with suboptimal glycemic control (HbA1c 7.5-12.0%) despite maximum tolerated doses of metformin, dipeptidyl-peptidase 4 inhibitor, and glimepiride with stable dosage for at least 3 months. Empagliflozin (25 mg/day) or dapagliflozin (10 mg/day) was added as a fourth OAD to the existing triple combination therapy at the physician's discretion. Efficacy outcomes included the change in HbA1c, fasting plasma glucose (FPG), and other cardiometabolic variables at 3 years. Safety outcomes included adverse events (AEs), hypoglycemia, volume depletion, nocturia, genitourinary tract infections and laboratory tests. RESULTS: A total of 362 patients were enrolled with empagliflozin (25 mg/day, n = 185) and dapagliflozin (10 mg/day, n = 177), respectively. At 3 years, the mean HbA1c reduction was -1.7% (SD 1.1) in the empagliflozin group vs -1.1% (1.3) in the dapagliflozin group (P = 0.001). FPG also showed a similar trend (-59.3 -53.3 mg/dL vs -47.4 -61.7 mg/dL, empagliflozin and dapagliflozin, respectively, P = 0.055). In terms of body weight, empagliflozin showed significantly greater reduction (-4.5 -2.5 kg vs -1.0 -3.3 kg, P = 0.024). The proportion of patients reporting total and serious AEs was similar between two groups. CONCLUSION: The efficacy of addition of SGLT2 inhibitors as a quadruple combination therapy has been sustained for 3 years. In general, empagliflozin treatment was better than dapagliflozin.
doi:10.1111/jdi.13662
fatcat:bkxcstwxvrbhzoz7g6drhxpdjm